ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors.
Lopez M, Crompot E, Josselin E, Farina A, Rubis M, Castellano R, Fares J, Wehbe M, Collette Y, Charafe E, Blanchin S, Romagne F, Pálfi A, Hechler T, Pahl A, Azim HA Jr, Lhospice F, Mamessier E, Bertucci F, Elands J, Préville X, Olive D.
Lopez M, et al. Among authors: castellano r.
Cancer Res Commun. 2024 Nov 1;4(11):2998-3012. doi: 10.1158/2767-9764.CRC-24-0176.
Cancer Res Commun. 2024.
PMID: 39440991
Free PMC article.